Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,091 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence.
Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Hide M, Kocatürk E, Magerl M, Makris M, Meshkova R, Saini SS, Sussman G, Toubi E, Zhao Z, Zuberbier T, Gimenez-Arnau A. Maurer M, et al. Among authors: canonica gw. Allergy. 2016 Aug;71(8):1210-8. doi: 10.1111/all.12901. Epub 2016 May 30. Allergy. 2016. PMID: 27038243
The clinical safety of H1-receptor antagonists. An EAACI position paper.
Passalacqua G, Bousquet J, Bachert C, Church MK, Bindsley-Jensen C, Nagy L, Szemere P, Davies RJ, Durham SR, Horak F, Kontou-Fili K, Malling HJ, van Cauwenberge P, Canonica GW. Passalacqua G, et al. Among authors: canonica gw. Allergy. 1996 Oct;51(10):666-75. doi: 10.1111/j.1398-9995.1996.tb02109.x. Allergy. 1996. PMID: 8904993 Review. No abstract available.
Local immunotherapy.
Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Björkstén B, Bousquet J, Caillot D, Canonica GW, Passalacqua G, Saxonis-Papageorgiou P, Valovirta E. Malling HJ, et al. Among authors: canonica gw. Allergy. 1998 Oct;53(10):933-44. doi: 10.1111/j.1398-9995.1998.tb03793.x. Allergy. 1998. PMID: 9821472 Review. No abstract available.
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Humbert M, et al. Among authors: canonica gw. Allergy. 2005 Mar;60(3):309-16. doi: 10.1111/j.1398-9995.2004.00772.x. Allergy. 2005. PMID: 15679715 Clinical Trial.
1,091 results